Dehydrocostus Lactone Inhibits Microglia‐Mediated Neuroinflammation by Targeting CYP2A6 to Improve Ischemic Brain Injury
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70502 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Xin Shu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Microglia, Lactones, Sesquiterpenes, Brain Ischemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau.
Abstract (Originalsprache)
Background
Neuroinflammation is an important factor in ischemic stroke. Dehydrocostus lactone (DHC) plays an anti‐inflammatory role in certain diseases. However, the role of DHC in neuroinflammation after ischemic stroke remains unclear.
Methods
DHC was administered to lipopolysaccharide (LPS)‐treated BV2 cells and a middle cerebral artery occlusion (MCAO) model to detect the levels of inflammatory factors using quantitative real‐time PCR, western blotting, and behavioral tests. Morphological changes in microglia were observed using immunofluorescence. The Swiss Target Prediction database was used to predict the target of DHC. Finally, a specific inhibitor of the target protein was used to investigate its potential synergistic role in neuroinflammation, both with and without being combined with DHC.
Results
The expression of inflammation‐related factors both in vivo and in vitro was improved by DHC, and the neurological deficits in mice after MCAO were improved in the DHC administration group. In addition, the Swiss Target Prediction showed that CYP2A6 was a target of DHC. Specifically, the combination of DHC with the CYP2A6 inhibitor showed that DHC exerts anti‐inflammatory effects in a CYP2A6‐dependent manner.
Conclusion
Mechanistically, DHC inhibited neuroinflammation by binding to the target CYP2A6. Our study suggests that DHC is a promising new strategy for treating ischemic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Practice, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China.
- Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of General Practice, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
ORCID-Profile: Dujuan Sha
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau
Zitieren
APA
Shu, X., Zou, X., Zhang, J., Fang, X., Wang, X., Wu, H., He, X., & Sha, D. (2025). Dehydrocostus Lactone Inhibits Microglia‐Mediated Neuroinflammation by Targeting CYP2A6 to Improve Ischemic Brain Injury. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70502
Vancouver
Shu X, Zou X, Zhang J, Fang X, Wang X, Wu H, et al. Dehydrocostus Lactone Inhibits Microglia‐Mediated Neuroinflammation by Targeting CYP2A6 to Improve Ischemic Brain Injury. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70502
BibTeX
@article{Shu2025,
author = {Shu, Xin and Zou, Xinxin and Zhang, Jingxuan and Fang, Xu and Wang, Xinyu and Wu, Hui and He, Xuan and Sha, Dujuan},
title = {Dehydrocostus Lactone Inhibits Microglia‐Mediated Neuroinflammation by Targeting CYP2A6 to Improve Ischemic Brain Injury},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70502}
}
EUVIMED